Pharmaceutical company engaged in the discovery and development of proprietary prodrugs
FDA regulation of opioid abuse deterrent formulations Prodrug therapies and improving abuse deterrence and consumer safety
Anti-opioid abuse deterrent legislation 
H.R. 6 (SUPPORT for Patients and Communities Act), provisions relating to HHS study on abuse deterrent formulations access barriers under Medicare
H.R. 5582 (Abuse Deterrent Access Act of 2018), all provisions
Pharmaceutical anti-opioid prodrug regulatory bill
PHA - Pharmacy HCR - Health Issues
2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE
ARENTFOX SCHIFF LLP
1717 K Street, NW, Washington, DC, 20006, US
PHILIP ENGLISH NORMAN FREDERICK LENT PHILIP ENGLISH NORMAN FREDERICK LENT SONJA NESBIT